PSC
OKUR

Piper Sandler & Co’s OnKure Therapeutics OKUR Stock Holding History

Piper Sandler & Co’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-98
Closed -$7K – 29
2021
Q3 		$7K Buy
+98
New +$8.32K 0.01% 19

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Piper Sandler & Co's OKUR Position: Q4 2021 in Review

Piper Sandler & Co sold out of OnKure Therapeutics (OKUR) in Q4 2021, closing a stake of 98 shares — an estimated $7K sold.

Piper Sandler & Co first reported a position in OKUR in Q3 2021 and held it in 1 quarter. The position peaked at $7K in Q3 2021. 39 funds tracked by Wall St. Rank hold OKUR as of Q4 2021.

  • Piper Sandler & Co reported no remaining OnKure Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Piper Sandler & Co sold 98 OnKure Therapeutics shares in Q4 2021, an estimated $7K.
  • Piper Sandler & Co first reported a position in OnKure Therapeutics in Q3 2021 and held it in 1 quarter.
  • Piper Sandler & Co's OnKure Therapeutics position peaked at $7K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2021.

Based on Piper Sandler & Co's 13F filing for Q4 2021, filed 14 Feb 2022.